Scarica l'app Stockscreener
27.67
4.52%
-1.31
Dopo l'orario di chiusura:
27.67
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GPCR Giù?
Forum
Previsione
Precedente Chiudi:
$28.98
Aprire:
$28.99
Volume 24 ore:
1.71M
Relative Volume:
2.12
Capitalizzazione di mercato:
$1.97B
Reddito:
-
Utile/perdita netta:
$-170.73M
Rapporto P/E:
-10.28
EPS:
-2.6921
Flusso di cassa netto:
$-159.70M
1 W Prestazione:
-22.99%
1M Prestazione:
-42.11%
6M Prestazione:
-48.26%
1 anno Prestazione:
+3.94%
Intervallo 1D:
$27.57
$29.25
Intervallo di 1 settimana:
$27.57
$35.64
Portata 52W:
$25.59
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Nome
Structure Therapeutics Inc Adr
Settore
Industria
Telefono
(650) 457-1978
Indirizzo
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
27.67 | 2.56B | 0 | -170.73M | -159.70M | -2.6921 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-27 | Iniziato | Canaccord Genuity | Buy |
| 2026-03-26 | Iniziato | Wolfe Research | Peer Perform |
| 2025-05-02 | Iniziato | Citigroup | Buy |
| 2025-02-28 | Iniziato | William Blair | Outperform |
| 2025-01-08 | Iniziato | Stifel | Buy |
| 2024-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-05-21 | Iniziato | JP Morgan | Overweight |
| 2024-04-09 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-07-27 | Iniziato | Piper Sandler | Overweight |
| 2023-05-25 | Ripresa | Jefferies | Buy |
| 2023-02-28 | Iniziato | BMO Capital Markets | Outperform |
| 2023-02-28 | Iniziato | Guggenheim | Buy |
| 2023-02-28 | Iniziato | Jefferies | Buy |
| 2023-02-28 | Iniziato | SVB Securities | Outperform |
Mostra tutto
Structure Therapeutics Inc Adr Borsa (GPCR) Ultime notizie
Rival Drug Breakthroughs Knock Structure Therapeutics Stock Lower - TipRanks
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), ClearPoint Neuro (CLPT) and Axsome Therapeutics (AXSM) - theglobeandmail.com
Biotech Chill Sends Structure Therapeutics Stock Tumbling - TipRanks
Southern Copper, Toll Brothers, Spruce Power, Structure Therapeutics, Verisign Insider Shake-Up - TipRanks
Structure Therapeutics Inc. (GPCR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wall Street Analysts Are Bullish on Top Healthcare Picks - theglobeandmail.com
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1? - Zacks Investment Research
Analysts’ Top NA Picks: MillerKnoll (MLKN), Telix Pharmaceuticals Limited Unsponsored ADR (TLX) - theglobeandmail.com
Form 4 Structure Therapeutics Inc ADR For: 22 September By Investing.com - Investing.com Canada
Structure Therapeutics (GPCR) CMO sells shares under preset plan - Stock Titan
Form 144 Structure Therapeutics Inc. For: 22 September By Investing.com - Investing.com Nigeria
Form 144 Structure Therapeutics Inc. For: 22 September - Investing.com India
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Planned $140K share sale by Structure Therapeutics (Nasdaq: GPCR) officer - Stock Titan
Structure Therapeutics Surges On Promising Obesity Drug Data - TipRanks
LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious? - TradingView
Structure Therapeutics at Morgan Stanley conference: oral pipeline gains ground - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: McKesson (MCK), AgomAb Therapeutics NV ADR (AGMB) and Solventum Corporation (SOLV) - theglobeandmail.com
Structure Therapeutics at Cantor conference: oral obesity push advances - Investing.com India
Price-Driven Insight from (GPCR) for Rule-Based Strategy - Stock Traders Daily
Structure Therapeutics at Cantor conference: oral obesity push advances By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail
Structure Therapeutics Advances ACCG-2671 with 3.3% Weight Loss; Aleniglipron Hits 16.2% Reduction (NASDAQ: GPCR) - Kalkine Media
Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Structure Therapeutics stock price target maintained at $70 by H.C. Wainwright - Investing.com Canada
Citizens reiterates Structure Therapeutics stock rating on trial data - investing.com
Citizens reiterates Structure Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Structure Therapeutics (GPCR) Shares Slide After Obesity Drug Tr - GuruFocus
Jefferies raises Structure Therapeutics stock target on amylin data By Investing.com - Investing.com Canada
Structure Therapeutics Reports Positive ACCG-2671 Early Trial Results - TipRanks
Oral obesity drug shows double-digit weight loss as Structure Therapeutics (NASDAQ: GPCR) advances Phase 3 trials - Stock Titan
A weight-loss pill cut body weight 16.2% in 72 weeks - Stock Titan
Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management - Yahoo Finance
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT) - theglobeandmail.com
Morgan Stanley’s conference is one of three Structure Therapeutics plans to join in September - Stock Titan
Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences - Yahoo Finance
Structure Therapeutics (GPCR) CSO sells 5,939 ADSs under preset plan - stocktitan.net
(GPCR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now? - Yahoo Finance
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX) - The Globe and Mail
Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s? - Eastern Progress
Handelsbanken Fonder AB Purchases Shares of 19,400 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (GPCR) exec sells 3,939 ADSs under plan - Stock Titan
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's? - TradingView
Structure Therapeutics IncADR (GPCR) News, Articles, Events & Latest Updates - Stocktwits
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock? - TradingView
Structure Therapeutics (NASDAQ:GPCR) Rating Increased to Sell at Wall Street Zen - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxis Oncology (PYXS) - The Globe and Mail
Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge? - TradingView
LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1? - TradingView
Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock? - TradingView
Structure Therapeutics Inc Adr Azioni (GPCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Structure Therapeutics Inc Adr Azioni (GPCR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lin Xichen | CHIEF SCIENTIFIC OFFICER |
Sep 01 '26 |
Option Exercise |
0.34 |
17,817 |
6,058 |
246,777 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER |
Aug 18 '26 |
Option Exercise |
0.34 |
11,817 |
4,018 |
240,777 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER |
Aug 04 '26 |
Option Exercise |
0.34 |
11,817 |
4,018 |
240,777 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER |
Jul 14 '26 |
Option Exercise |
0.34 |
23,634 |
8,036 |
252,594 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER |
Jun 25 '26 |
Option Exercise |
0.34 |
23,634 |
8,036 |
252,594 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):